WHO studies of course and outcome of schizophrenia

The WHO International Pilot Study of Schizophrenia (IPSS) was set up to examine the feasibility of making cross-culturally reliable diagnosis of the disorder and to demonstrate the existence of schizophrenia in diverse cultural settings. ⁴ In conducting a follow-up on the cohort, the investigators unexpectedly found a markedly better overall outcome in individuals with schizophrenia in India and Nigeria at 2 and 5 years. A subsequent study, designed to be more epidemiologically rigorous and therefore more representative, the Determinants of Outcome of Severe Mental Disorders (DOSMeD), later confirmed these findings. ^{Reference Jablensky, Sartorius, Ernberg, Anker, Korten and Cooper6} High rates of complete clinical remission were significantly more common in low- and middle-income countries (37%) than in high-income countries (15.5%). Also, even though individuals in low- and middle-income countries were much less likely to be on continuous antipsychotic medication, they nevertheless experienced significantly longer periods of unimpaired functioning when compared with individuals from the high-income country study sites. Even then, the findings were more indicative of a diversity of outcomes rather than any culture-specific pattern of outcome. For example, there was no significant difference in the proportions of continuous unremitting illness (11.1 and 17.4%) across the two types of settings. The International Study of Schizophrenia, ^{Reference Hopper, Harrison, Janca and Sartorius5} which was a long-term follow-up of participants in IPSS and DOSMeD, supported the earlier findings.

Irrespective of the findings reported by these studies, it is clear that most commentators have not given their findings the nuanced interpretation that the results deserve. Thus, it is true that it has almost become axiomatic to claim that schizophrenia has a better course and outcome in low- and middle-income countries. ^{Reference Cohen, Patel, Thara and Gureje7} The situation has not been helped by the lack of studies of comparable rigor and coverage that would provide convincing refutation or replication of the main findings of the WHO studies. Nevertheless, evidence from several other studies, albeit of diverse coverage and rigor, suggests that the strikingly better outcome reported for a substantial proportion of participants from low- and middle-income country sites in the WHO studies may have been atypical of people with schizophrenia from those countries. ^{Reference Cohen, Patel, Thara and Gureje7}

The importance of differential outcome

The suggestion that schizophrenia might have a better outcome in settings grouped together on the basis of comparable social factors provides a compelling research question. This is so because, other than biological and individual factors such as genetic vulnerability, the influence of which remains indeterminate, environmental, including sociocultural, factors are of particular importance in disentangling prognostic features. Of course, subsumed under sociocultural factors are a great many variables of different complexities both in their assessment and in their interpretation. ^{Reference Edgerton and Cohen8}

More studies examining differential outcomes in diverse sociocultural settings are therefore needed, and the study by Haro et al in this issue of the Journal is an important addition to the literature. ^{Reference Haro, Novick, Bertsch, Karagianis, Dossenbach and Jones9} Its strengths include a large sample, serial assessments that utilised standard operational definitions of outcomes and wide geographic diversity. Nevertheless, we think they have allowed the interpretation of their findings to be influenced by those of the ‘axiomatic’ WHO studies. Thus, even though they state that their ‘… findings support the earlier WHO studies reporting differences in outcomes between regions’, ^{Reference Haro, Novick, Bertsch, Karagianis, Dossenbach and Jones9} a closer look at the methodology of the study suggests that the results deserve a more tentative interpretation. First, it is largely a study of prevalent cases that were initiating new antipsychotic treatment or requiring a change in medication (with only 9% being never treated). Second, the samples varied in the mean duration of illness from 8 to 12 years and in the proportions with a history of substance misuse from 3 to 12%. However, in order to truly provide answers germane to the determination of differential outcome of schizophrenia across settings, studies need to be of incident cases, preferably defined as first episode and untreated. Anything less rigorous invites selection bias, especially when samples are derived from treated populations given that factors relating to access to services and pathways to care vary enormously across settings and, thus, introduce varying levels of chronicity and comorbidity. To be fair, the authors have attempted to account for this in the statistical approach they have employed but this is difficult given that there is little evidence that selection bias is the same in all settings.

Haro et al also make the observation that although North Africa/Middle East had a similar clinical outcome profile with Latin America, the two regions were widely divergent with regard to functional outcome. The same pattern of inconsistent outcome profiles is seen when Northern Europe is compared with Southern Europe, even though both belong to the ‘high-income’ countries grouping. Clearly, if a neat interpretation of similar outcomes according to developmental stage was applicable, it would be plausible to expect functional outcomes to be more similar within countries with comparable sociocultural and economic status. Of course, even though clinical and functional outcomes can be expected to be unidirectional, one should not dismiss the possibility of discordance given the finding by Strauss & Carpenter of ‘open-linked’ systems of outcomes. ^{Reference Strauss and Carpenter10} That aside, functional remission is a complex multidimensional concept to assess. Its measurement is made even more difficult when trying to compare it across diverse settings. ^{Reference Isaac, Chand and Murthy11} Therefore, one must wonder whether the definition of functional remission used in this study meant the same thing in the different settings, especially when it does not appear that the cross-cultural validity and reliability of this definition has been determined.

Conducting comparative outcome studies of schizophrenia

The challenges of conducting ecological epidemiological studies that will throw light on differential outcomes of schizophrenia, although not insurmountable, are nevertheless considerable. ^{Reference Andreasen, Carpenter, Kane, Lasser, Marder and Weinberger12} One of the challenges relates to definitional issues, especially when variables are capturing factors of divergent social or cultural import. Features such as occupational/vocational status and extent and nature of social interactions are problematic to define in ways that do sufficient justice to cultural and social diversity while still making it possible to carry out cross-site comparisons. Furthermore, it may not be valid to make cross-cultural comparisons of rates of marriage among people with schizophrenia because the institution of marriage is shaped by social and cultural forces that exert far more influence than psychiatric diagnosis. As demonstrated elsewhere, ^{Reference Cohen, Patel, Thara and Gureje7} it is better to compare marriage rates of people with schizophrenia to the rates found among the general populations in which they live. When this is done, it becomes clear that individuals with schizophrenia have rates of marriage that are relatively low and rates of separation and divorce that are relatively high. Information on mortality, another important outcome variable, does not provide clarity about differential outcome. A recent systematic review of mortality in schizophrenia found no significant difference in standardised mortality ratios between sites grouped according to their economic status. ^{Reference Saha, Chant and McGrath13}

Interpreting findings on the comparative outcomes of schizophrenia in clinical samples drawn from high-income countries with those from low- and middle-income countries is made more difficult by findings suggesting that a high proportion of people with psychosis in the community in low- and middle-income countries may not have received any formal treatment. ^{Reference Gureje, Olowosegun, Adebayo and Stein14} Thus, those who do may represent an atypical group. In addition, the forced dichotomy of ‘high-income’ and ‘low- and middle-income’ settings tends to ignore the diverse social, cultural and economic factors embedded within those terms. Although the dichotomy may provide a useful way of exploring a large data-set, it is important not to stretch the implied uniformity between and within the countries so grouped beyond the very rudimentary.

Studies examining the differential outcome of schizophrenia in diverse settings with clearly defined and measurable characteristics are of potential importance in understanding sociocultural factors that may be relevant to the course of the disorder. Such studies need not be limited to between-nation comparisons, but could usefully examine within-nation differences in outcome as well since it is plausible to expect that factors such as urbanicity, migrant status and neighbourhood-level variables related to social capital may influence course and outcome. ^{Reference McGrath15}